Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hanover – page 34

637 clinical trials in Hanover, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hanover at a glance
637
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

637 trials in Hanover

Open in trial search

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab and Tremelimumab with Y-90 SIRT for Patients with Intermediate Stage Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rly-4008
  • Sponsor:Elevar Therapeutics Inc.

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cx-037231
  • Sponsor:Moderna Therapeutics Inc.

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Dilated cardiomyopathy

Not recruiting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ab-1002
  • Sponsor:Askbio Inc.

Primary biliary cholangitis

Not recruiting

Study on Elafibranor for Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Pharma

Thalassaemia beta

Not recruiting

Long-Term Safety and Efficacy Study of Betibeglogene Autotemcel Gene Therapy for Patients with Transfusion-Dependent Beta-Thalassemia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Betibeglogene Autotemcel
  • Sponsor:Genetix Biotherapeutics Inc.

Non-small cell lung cancer

Not recruiting

Study of Chemotherapy with Osimertinib in Non-Small Cell Lung Cancer Patients Who Have Progressed After Initial Osimertinib Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Hepatitis D+1

Not recruiting

Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hanover

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory infections and conditions, including studies of vaccines against RSV and human metapneumovirus in older adults. Research also includes treatment evaluation for chronic obstructive pulmonary disease.

  • RSV vaccine development
  • COPD treatment innovations
  • Viral respiratory infections

Multiple studies are evaluating novel therapeutic approaches for both acute and chronic respiratory conditions.

02 Oncology Research

Innovative trials in cancer treatment, including studies for bladder cancer, multiple myeloma, and advanced breast cancer. Research focuses on combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Blood cancer treatments
  • Targeted therapies

Studies emphasize personalized treatment approaches and immune system-based therapies.

03 Neurological Conditions

Research focusing on neurodegenerative diseases, particularly Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Studies evaluate new diagnostic tools and therapeutic interventions.

  • Early-stage dementia treatment
  • ALS therapeutic development
  • Brain clearance mechanisms

Trials aim to address both symptomatic treatment and disease progression.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.